Malignant Melanoma Clinical Trial
Official title:
Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
NCT number | NCT01017185 |
Other study ID # | M06-10083 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | August 2009 |
Est. completion date | March 2015 |
Verified date | May 2015 |
Source | Takara Bio Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.
Status | Completed |
Enrollment | 28 |
Est. completion date | March 2015 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria - Patients must have histologically confirmed solid tumors that have failed standard therapies (surgery, chemotherapy, radiotherapy, or endocrine therapy) and for which no curative options exist, including, but not limited to: - Squamous cell carcinoma of the head and neck - Squamous cell carcinoma of the skin - Carcinoma of the breast - Malignant melanoma - Patients may have had any kind and number of prior cancer therapies. - Patients must have measurable non-visceral lesions that are evaluable by the RECIST method - The tumor mass to be treated must be non-visceral and adequate for injection (i.e., more than 2 cm away from major vascular structures) and measurement by RECIST. - Patients in Stage 1 must be seropositive for HSV-1. - The first patient enrolled into each cohort in Stage 2 must be seropositive for HSV-1. - Patients must be = 18 years of age. - Patients must have a life expectancy = 12 weeks - Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. - Patients must have adequate hepatic function, as defined as - Total bilirubin levels = 1.5 x upper limit of normal (ULN) - AST/ALT levels = 2.5 x ULN, or = 5 x ULN if liver metastases are present - Patients must have adequate renal function as defined as serum creatinine = 1.5 x ULN or creatinine clearance (calculated) = 60 mL/min/1.73 m2 for patients with creatinine > 1.5 x ULN - Patients must have adequate bone marrow function, as defined as - Absolute neutrophil count = 1,500/µL and - Platelet count = 100,000/µL - Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe. - Men and women of childbearing potential must agree to use adequate contraception prior to study entry and for up to six months. - Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment. - Patients must be able to understand and willing to sign a written informed consent document. Exclusion Criteria - Patients receiving chemotherapy or radiotherapy within 4 weeks of injection of HF10, or adverse events > Grade 1, except alopecia, resulting from agents administered more than 4 weeks prior to HF10 injection. - Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders. - Patients with nasopharyngeal tumors. - Patients with deep (below the platysma muscle layer) ulcerative tumors. - Patients with target tumors that could potentially invade a major vascular structure(s) (e.g., innominate artery, carotid artery), based on unequivocal imaging findings, as determined by a radiologist. - Patients with Grade = 1 pre-existing neurologic abnormalities (CTCAE version 3.0). - Patients who have been hospitalized for emergent conditions requiring inpatient evaluation, treatment or procedure during the 30 days prior to entry on study. In addition, emergent conditions requiring inpatient evaluation, treatment or procedure must have resolved or be medically stable and not severe for 30 days prior to entry on study. - Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection. Patients will be tested for HIV during pre-treatment screening. - Patients receiving steroids or immunosuppressive agents, e.g., for rheumatoid arthritis - Concurrent use of any other investigational agents. - Presence or history of central nervous system metastasis. - Pregnant or breastfeeding women;women desiring to become pregnant within the timeframe of the study are also excluded. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. |
Country | Name | City | State |
---|---|---|---|
United States | Montefiore Medical Center | Bronx | New York |
United States | Mary Crowley Cancer Research Center | Dallas | Texas |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Huntsman Cancer Institute | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Takara Bio Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the local tumor response of the HF10-injected tumor by a modified target Response Evaluation Criteria In Solid Tumors (RECIST) method | one year | ||
Secondary | Adverse events, vital signs, electrocardiogram(ECG), clinical laboratory tests, and physical exercise | one year | ||
Secondary | Histological tumor response by biopsy | one year | ||
Secondary | Overall tumor response of the HF10-injected tumor plus additional non-injected target tumors. | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04229277 -
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
|
N/A | |
Completed |
NCT03653819 -
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
|
N/A | |
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Completed |
NCT02935790 -
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
|
Phase 1 | |
Recruiting |
NCT05478876 -
Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract
|
N/A | |
Completed |
NCT01211262 -
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
|
Phase 1 | |
Recruiting |
NCT03649529 -
Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy
|
Early Phase 1 | |
Completed |
NCT03278665 -
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT04452214 -
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
|
Phase 1 | |
Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01455259 -
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00978913 -
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma
|
Phase 1 | |
Completed |
NCT00232726 -
Clinical Study of Previously Untreated Patients With Malignant Melanoma
|
Phase 2 | |
Completed |
NCT00350597 -
GM-CSF as Adjuvant Therapy of Melanoma
|
Phase 2 | |
Completed |
NCT00336986 -
Efficacy Study of IL-21 to Treat Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT02523313 -
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
|
Phase 2 | |
Completed |
NCT03545334 -
Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study
|
N/A | |
Completed |
NCT04253574 -
Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
|
||
Completed |
NCT00179608 -
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
|
Phase 1 | |
Terminated |
NCT00104884 -
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
|
Phase 2 |